Although interleukin (IL)-33 is a candidate for the aggravation of asthma, the mechanisms underlying antigen-specific IL-33 production in the lung are unclear. Therefore, we analysed the mechanisms in mice. Intra-tracheal administration of ovalbumin (OVA) evoked increases in IL-33 and IL-33 mRNA in the lungs of both non-sensitized and OVA-sensitized mice, and the increases in the sensitized mice were significantly higher than in the non-sensitized mice. However, intra-tracheal administration of bovine serum albumin did not increase the IL-33 level in the OVA-sensitized mice. Depletion of neither mast cells/basophils nor CD4 + cells abolished the OVA-induced IL-33 production in sensitized mice, suggesting that the antigen recognition leading to the IL-33 production was not related with either antigen-specific IgE-bearing mast cells/basophils or memory CD4 + Th2 cells. When a fluorogenic substrate-labelled OVA (DQ-OVA) was intra-tracheally administered, the lung cells of sensitized mice incorporated more DQ-OVA than those of non-sensitized mice. The lung cells incorporating DQ-OVA included B-cells and alveolar macrophages. The allergic IL-33 production was significantly reduced by treatment with anti-FccRII/III mAb. Depletion of alveolar macrophages by clodronate liposomes significantly suppressed the allergic IL-33 production, whereas depletion of B-cells by anti-CD20 mAb did not. These results suggest that the administered OVA in the lung bound antigen-specific IgG Ab, and then alveolar macrophages incorporated the immune complex through FccRII/III on the cell surface, resulting in IL-33 production in sensitized mice. The mechanisms underlying the antigen-specific IL-33 production may aid in development of new pharmacotherapies.
Introduction
Interleukin (IL)-33, a member of the IL-1 family of cytokines, 1 is expressed at higher levels in the lungs of human asthma patients than in those of control subjects. 2 The expression of IL-33 was particularly evident in the lungs of patients with severe asthma, including steroid-resistant asthma. [2] [3] [4] Indeed, it has been reported that IL-33 activates a wide variety of immune cells, including mast cells, basophils, macrophages, dendritic cells, Th2 cells and type 2 innate lymphoid cells (ILC2), through the cell surface IL-33 receptor, ST2, leading to the production of several proinflammatory molecules. 1, [5] [6] [7] [8] As such, IL-33 may function as a key molecule bridging innate and acquired immune cells in the pathogenesis of asthma. Thus, elucidation of the mechanisms underlying allergic IL-33 production and its functional roles may be useful for the development of new pharmacotherapies for asthma. Extensive research has been conducted to understand the functional roles of IL-33 in the asthma pathogenesis, [2] [3] [4] [5] [6] [7] [8] but the mechanisms of allergic IL-33 production remain unclear.
IL-33 was originally identified as a nuclear protein in endothelial cells, and then found to be produced by not only endothelial cells, but also epithelial cells, smooth 
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muscle cells, fibroblasts and haematopoietic cells, especially macrophages. 1, 5 It has been reported that IL-33 is released during necrosis. 1, 6 In allergic diseases, the use of murine pollinosis models has clarified that IL-33 is constitutively expressed in the conjunctival epithelial cells, 9 and that challenge with a topical ragweed allergen elevated IL-33 mRNA levels in conjunctival tissue 24 hr after the challenge. 9 Using a murine model of asthma, we and others demonstrated that IL-33 is produced in the lung upon exposure to antigens such as ovalbumin (OVA) [10] [11] [12] [13] and house dust mite.
14 These findings strongly suggested that antigen challenge induces the transcription of IL-33 mRNA, leading to the synthesis of the IL-33 protein in the lung. However, it was also reported that antigen exposure-induced IL-33 production in the airway epithelial cells was dependent on the innate immune response through toll-like receptor (TLR) 4. 14 Collectively, it is unclear whether mechanisms underlying antigen-induced IL-33 production include specific antigen-dependent acquired immune responses, and it is unknown which immune component cells are involved in the antigen recognition leading to airway IL-33 production.
The purpose of the present study was to elucidate: (i) whether mechanisms underlying antigen-induced airway IL-33 production in the sensitized mice are specific antigen-dependent; and (ii) which immune cells and molecules are involved in recognition of the specific antigen in the lung to lead the allergic IL-33 production.
Materials and methods

Sensitization and challenge
As reported previously, 11, [15] [16] [17] [18] 5-week-old BALB/c mice (Japan SLC, Hamamatsu, Japan) were sensitized by intraperitoneal (i.p.) injections with OVA (Grade V; Sigma Chem., St Louis, MO) adsorbed to Al(OH) 3 at a dose of 50 lg OVA/2 mg Al(OH) 3 /0Á5 ml saline/animal on days 0, 14 and 28. Then, the sensitized mice were challenged on day 35 under inhalation anaesthesia with isoflurane with 2% OVA at a volume of 25 ll intra-tracheally. In place of OVA, 2% bovine serum albumin (BSA; Sigma Chem.) was intra-tracheally administered at a volume of 25 ll. For non-sensitized groups, saline or Al(OH) 3 was i.p. administered on days 0, 14 and 28.
This animal study was approved by the Experimental Animal Research Committee at Setsunan University and Kyoto Pharmaceutical University.
Treatment with anti-FceRI mAb, anti-CD4 mAb, anti-CD20 mAb, anti-FccRII/III mAb or clodronate liposomes Sensitized mice were treated with anti-FceRIa mAb, MAR-1 or hamster IgG (Thermo Fisher Scientific, Waltham, MA), or phosphate-buffered saline (PBS) three times at 25, 13 and 1 hr before the challenge at a dose of 10 lg/animal (i.p.). We previously reported that both mast cells and basophils were depleted by a protocol conducted according to the present method. 18. A cell line producing rat IgG2b mAb that recognizes the murine CD4 molecule (YTS191Á1Á2) was kindly provided by Prof. David D. Chaplin (University of Alabama at Birmingham, Birmingham, AL). The hybridoma cells were cultured and grown, and then i.p. injected into severe combined immunodeficiency mice that had been treated with pristane. Ascites fluid was collected 10-14 days after the injection. IgG was purified by protein G affinity chromatography, followed by desalting using PD-10 column chromatography. The purified anti-CD4 mAb, rat IgG (Sigma Chem.) or PBS was i.p. administered once 18 hr prior to the antigen challenge at a dose of 0Á6 mg/animal. We have reported near complete depletion of CD4 + cells in the lung, spleen and peripheral blood using this protocol. 16 For depletion of B-cells, anti-CD20 mAb, 5D2, 19 kindly donated by Genentech (San Francisco, CA), was intravenously (i.v.) administered 3 days before the challenge at a dose of 0Á4 mg/animal. PBS or rat IgG was administered for control groups.
A cell line producing rat IgG2b mAb that recognizes the murine FccRII/III molecule (2Á4G2) was purchased from American Type Culture Collection (Manassas, VA). The anti-FccRII/III antibody was collected and purified in the same manner as the anti-CD4 mAb. As previously reported, 20 the anti-FccRII/III antibody was used to specifically block cell surface FccRII/III. The anti-FccRII/ III mAb, rat IgG or PBS was i.p. administered once 24 hr prior to the antigen challenge at a dose of 0Á5 mg/animal.
For reduction of alveolar macrophages, clodronate liposomes (Clophosome â ; FormuMax Scientific, Sunnyvale, CA) were intra-tracheally administered twice at a volume of 25 ll/animal in a 6-hr interval 3 days before the challenge. PBS or control liposomes (FormuMax Scientific) were administered for control groups.
Measurement of the amount of IL-33 and IL-33 mRNA in the lungs
The lungs were isolated under anaesthesia with pentobarbital and xylazine before or 4 hr after the OVA challenge. The right lobes were homogenized in 1 ml of protease inhibitor cocktail tablet (Complete, Mini â ; Roche, Mannheim, Germany)-containing tissue protein extraction reagent (T-PER; Thermo Fisher Scientific). Following centrifugation, the amount of IL-33 in the supernatant was assayed by the ELISA kit (Thermo Fisher Scientific).
The isolated left lobes were homogenized in 0Á5 ml of RNAiso Plus â (Takara, Otsu, Japan 21 and the house-keeping gene, 36B4 mRNA (Nippon Gene), 11 and the mixture were heated at 95°for 30 seconds to activate SYBR Premix Ex Taq TM . Denaturation (95°, 30 seconds), and annealing and extension (63°, 34 seconds) were repeated for 45 cycles. The melting curve of each primer set was then acquired by increasing the temperature from 60°to 95°using the LightCycler Nano 1Á1 software (Roche). The relative standard curve method was used to analyse the expression level of IL-33 mRNA.
Detection of alveolar macrophages, dendritic cells and Bcells in the lung
The lobes of the lungs were isolated under anaesthesia with pentobarbital and xylazine before and 4 hr after the OVA challenge. The tissue was cut into approximately 1 9 1 9 1-mm pieces, followed by incubation with 3 mg/ml collagenase type-I (220 U/mg; Thermo Fisher Scientific) at 37°for 1 hr. Cells were dispersed using a syringe, and then filtrated through 70-lm nylon mesh. After centrifugation, contaminating erythrocytes were lysed with ACK lysing buffer.
Lung cells were treated with an anti-CD16/32 (FccRII/ III) antibody (2Á4G2) to prevent the non-specific binding of subsequently used antibodies to the cells. 
Incorporation of DQ-OVA by lung cells in vitro
As described above, the lobes of the lungs were isolated under anaesthesia before the OVA challenge. The tissue was cut into approximately 1 9 1 9 1-mm pieces, followed by incubation with 3 mg/ml collagenase type-I (220 U/mg) at 37°for 1 hr. Cells were dispersed using a syringe, and then filtrated through 70-lm nylon mesh. After centrifugation, contaminating erythrocytes were lysed with ACK lysing buffer. The single cells were suspended in 10% FBS-containing RPMI1640 medium at 5 9 10 5 cells/250 ll/well. Pooled serum collected from the saline-treated or OVA+Al(OH) 3 -sensitized mice was added to the single cell suspension at a volume of 2Á5 ll/well. Ten minutes after the serum addition, DQ-OVA was added to make a final concentration of 10 À6 g/ml, followed by incubation at 37°for 30 min. Then, the incubated cells were washed twice with PBS. Flow cytometry detection of DQ-OVA-incorporated alveolar macrophages, dendritic cells and B-cells were conducted as described above.
Immunohistochemical detection of IL-33-producing alveolar macrophages
Before and 4 hr after the OVA challenge, the lung was perfused with approximately 5 ml PBS, and then approximately 100 ml 10% buffered formalin under the anaesthesia with pentobarbital and xylazine. Then, the left lobes of the lungs were isolated, and cut into three sections, followed by immersion in 10% buffered formalin. The fixed tissues were embedded in paraffin, and cut into 4-lm-thick sections. IL-33-and F4/80-positive cells were detected using sequentially cut sections by immunohistochemistry. Antigenicity in the tissue sections was generally activated by immersion of the sections on slides in Histo VT one (Nacalai Tesque, Kyoto, Japan). After washing, the sections were treated with 3% hydrogen peroxidemethanol solution. Following washing, the sections were treated with diluted rabbit normal serum (Vector Lab., Burlingame, CA) at room temperature for 30 min in order to prevent non-specific binding of the secondary antibody. After washing, tissue sections were stained with anti-mouse IL-33 (AF3626, 5 lg/ml) or normal goat IgG (AB-108-C, 5 lg/ml; R&D Systems, Minneapolis, MN), or anti-mouse F4/80 (BM8, 12Á5 lg/ml) or rat IgG2a, k isotype control (RKT2758, 12Á5 lg/ml; BioLegend) at room temperature for 1 hr. After washing, sections were stained with biotinylated anti-goat IgG antibody (1:200) or biotinylated anti-rat IgG antibody (1:200; Vector Lab.) at room temperature for 30 min. After washing, tissue sections were stained with a mixture of reagent A (avidin DH) and reagent B (biotinylated horseradish peroxidase H; both from Vector Lab.) at room temperature for 30 min, followed by colour development using ImmPACT TM DAB (Vector Lab.), and then counterstaining with haematoxylin solution.
Statistical analyses
A one-way analysis of variance (ANOVA) was performed. If significant differences were detected, individual group differences were determined by Dunnett's tests. The unpaired t-test was used to compare between two groups. 3 or OVA+Al(OH) 3 on days 0, 14 and 28, and then OVA was intra-tracheally administered on day 35. Before or 4 hr after the OVA administration, the lungs were isolated for measurement of IL-33 and IL-33 mRNA. Each point represents individual value. Mean AE SEM of three-six animals are also shown. *P < 0Á05; **P < 0Á01; ***P < 0Á001. A probability value (P) below 0Á05 was considered significant. These statistical analyses were conducted using JMP â Pro 11.2.0 (SAS Institute Japan, Tokyo, Japan).
Results
Antigen challenge-induced production of IL-33 in sensitized mice
Single intra-tracheal administration of OVA induced increases in both IL-33 protein and mRNA levels in the lungs of non-sensitized mice, although not significantly (Fig. 1a,b) . However, when the OVA+Al(OH) 3 -sensitized mice were challenged with OVA, significantly more IL-33 protein and mRNA were produced than in OVA-challenged, non-sensitized mice (Fig. 1a,b) . On the other hand, when BSA was used as a challenge antigen in place of OVA, IL-33 was not produced in any non-sensitized or OVA+Al(OH) 3 -sensitized mice ( Table 1) .
Effects of depletion of mast cells/basophils or CD4 + cells on the antigen challenge-induced production of IL-33
The anti-FceRI mAb MAR-1 was administered 1 day before the OVA challenge. We previously reported that this protocol led to depletion of mast cells and basophils in the lungs of sensitized mice. 18 However, the antigeninduced IL-33 production in the lungs was not affected (Fig. 2a) .
On the other hand, we also reported that treatment with the anti-CD4 mAb YTS191Á1Á2 1 day before the OVA challenge depleted CD4 + cells in the lungs, spleen and peripheral blood in sensitized mice. 16 Even after depletion of CD4 + cells, the antigen-induced airway IL-33 production was not affected (Fig. 2b) .
Incorporation of OVA by lung cells of the sensitized mice
Using DQ-OVA as a probe, we examined whether OVA was antigen-specifically incorporated into the lung cells of sensitized mice in vivo. Lung cells of the sensitized mice incorporated markedly higher amounts of DQ-OVA in Before BSA administration 4Á6 AE 1Á4 3Á0 AE 0Á9 5Á2 AE 1Á9 4 hr after BSA administration 4Á1 AE 0Á7 3Á8 AE 0Á3 5Á9 AE 1Á9 Mice were intraperitoneally (i.p.) sensitized with saline, Al(OH) 3 or OVA+Al(OH) 3 on days 0, 14 and 28, and then bovine serum albumin (BSA) was intra-tracheally challenged on day 35. Four hours after the BSA administration, the lungs were isolated for measurement of IL-33. Each value represents the mean AE SEM of three animals. IL, interleukin; OVA, ovalbumin. comparison with those of the non-sensitized mice (Fig. 3a,c) . The lung cells were digested by collagenase, and which cells incorporated OVA was analysed (Fig. 3c,  d) . As a result, 24Á7 AE 3Á5% (n = 5) of the OVA-incorporating cells were B-cells (CD45 + B220 + cells). In addition, 6Á8 AE 2Á7% (n = 5) and 10Á2 AE 6Á3% (n = 5) of the cells were alveolar macrophages (CD45 + CD11c + F4/80 + cells) and dendritic cells (CD45 + CD11c + I-A/I-E + cells), respectively (Fig. 3a,d) . Unfortunately, other cell types incorporating the OVA protein have not been clarified.
On the other hand, DQ-BSA was not incorporated in OVA+Al(OH) 3 -sensitized mice, whereas the lung cells of BSA+Al(OH) 3 -sensitized mice incorporated DQ-BSA with statistical significance (Fig. 3b) .
Effects of anti-FccRII/III mAb on the incorporation of OVA and antigen challenge-induced production of IL-33
We next examined whether the phagocytosis of DQ-OVA was mediated by FccRII/III on the cell surface of B-cells, alveolar macrophages and dendritic cells. Blocking of FccRII/III by the anti-FccRII/III mAb 2Á4G2 almost completely abolished the incorporation of DQ-OVA in Bcells, alveolar macrophages and dendritic cells (Fig. 4a) . Furthermore, the OVA-induced IL-33 production was also attenuated by the anti-FccRII/III mAb (Fig. 4b) .
Effects of depletion of B-cells on the antigen challenge-induced production of IL-33
As B-cells antigen-specifically incorporated OVA (Fig. 3a) , we examined whether B-cells were involved in the antigenspecific production of IL-33 in the lungs. As reported previously, 19 the anti-CD20 mAb 5D2 nearly depleted the lungs of all B-cells (CD45 + B220 + cells; Fig. 5a ). The number of B-cells (CD45 + B220 + cells) in the spleen was also markedly decreased by the anti-CD20 mAb (Fig. 5a) . However, the IL-33 production was not affected even by the near complete depletion of B-cells (Fig. 5b) .
Effects of reduction of alveolar macrophages on the antigen challenge-induced production of IL-33
As alveolar macrophages also antigen-specifically incorporated OVA (Fig. 3a) , the relationship between alveolar macrophages and the antigen-induced IL-33 production in the lungs was examined. As expected, intra-tracheal administration of clodronate liposomes significantly reduced the number of alveolar macrophages (CD45 + CD11c + F4/80 + cells) in the lung (Fig. 6a) , whereas dendritic cells (CD45 + CD11c + I-A/I-E + cells) were unaffected by clodronate liposomes (Fig. 6b) . OVAinduced IL-33 production was significantly suppressed by the reduction of alveolar macrophages in the lung (Fig. 6c) .
In vitro incorporation of OVA by lung cells in the presence of sensitized mouse serum It was examined whether the incorporation of OVA by alveolar macrophages can be reproduced in vitro. Unfortunately, the lung cells including alveolar macrophages isolated from the OVA+Al(OH) 3 -sensitized mice did not incorporate DQ-OVA in higher quantity than the cells isolated from saline-and Al(OH) 3 -treated animals (Fig. 7a,b) . However, interestingly, when serum collected from the OVA+Al(OH) 3 -sensitized mice was added to the culture system, the OVA incorporation was dramatically increased (Fig. 7a,b) . Degrees of OVA incorporation in the presence of the sensitized mouse serum by the lung cells including alveolar macrophages were not significantly different among saline-treated, Al(OH) 3 -treated and OVA+Al(OH) 3 -treated groups (Fig. 7a,b) .
Immunohistological detection of IL-33-producing cells in the lung
Compared with the lung histology of the non-challenged mice (Fig. 8a) , after the antigen challenge, the immunoreactivity of IL-33 was potentiated in the bronchial epithelial cells and smooth muscle cells, and leucocytes at the alveolar site (Fig. 8b) . As shown in the tissue sections that were sequentially cut (Fig. 8b,iii,iv) , the IL-33-immunoreactive leucocytes were in part F4/80-positive cells (macrophages).
Discussion
First, we assessed whether the mechanisms underlying the intra-tracheal antigen exposure-induced airway IL-33 production were antigen-specific. Airway OVA exposure evoked increases in IL-33 expression at both protein and mRNA levels even in non-sensitized mice. Compared with the levels of IL-33 and IL-33 mRNA in OVA-exposed, non-sensitized mice, those in OVA+Al(OH) 3 -sensitized mice were significantly higher. Moreover, BSA did not promote IL-33 production in the lungs of the sensitized mice. Thus, the OVA-induced airway IL-33 production in the sensitized mice included mechanisms associated with not only innate immunity but also antigen-specific acquired immunity. Hammad et al. 14 demonstrated that airway exposure to house dust mites induced IL-33 production in mice, and that the airway IL-33 production was dependent on TLR4 activation in airway epithelial cells. Like house dust mites, the OVA used in the present study was not endotoxin-free. Thus, OVA-induced airway IL-33 production even in the non-sensitized mice was induced by innate immune responses associated with TLR4 activation. In this study, we focused on the acquired immune mechanisms involved in further promotion of IL-33 production in the OVA+Al(OH) 3 sensitized mice was evaluated. Unexpectedly, the depletion of neither mast cells/basophils nor CD4 + cells affected the OVA-induced airway IL-33 production in the sensitized animals. As previously reported, [26] [27] [28] the antiFceRI mAb and anti-CD4 mAb successfully depleted mast cells/basophils and CD4 + cells in mice, and eliminated the functions of these cells. 16, 18 According to these results, neither antigen-specific IgE-bearing mast cells/basophils nor antigen-specific Th2 cells being presented the antigen by antigen-presenting cells were involved in the acquired immune mechanisms associated with the airway IL-33 production.
However, it was unclear how the immune component cells recognized specific antigens in the lungs. Thus, we focused on phagocytosis of OVA by the lung cells. DQ-OVA was used as an OVA probe because it becomes a fluorogenic substance once incorporated and digested by intracellular proteases. Similar with antigen-induced IL-33 production, the lung cells of sensitized mice incorporated more DQ-OVA than those of non-sensitized mice. FACS analyses clarified that the lung cells incorporating DQ-OVA included B-cells, alveolar macrophages and dendritic cells. The results indicated that antigen-specific mechanisms existed prior to the incorporation of antigens by the lung cells.
In the OVA-sensitized mice, i.p. sensitization three times with OVA+Al(OH) 3 produced large amounts of not only antigen-specific IgE antibody but also antigen-specific IgG antibody in the serum. 15 Thus, the OVA-IgG antibody immune complex may be incorporated into the lung cells, including B-cells, alveolar macrophages and dendritic cells, through the IgG receptor FccRII/III on the cell surface. We next examined the effects of anti-FccRII/ III mAb on the incorporation of DQ-OVA by the lung cells and airway IL-33 production in the sensitized mice. As expected, the neutralization of FccRII/III by the mAb almost completely abolished the incorporation of DQ-OVA into B-cells, alveolar macrophages and dendritic cells, and partially suppressed the OVA-induced IL-33 production in the lungs. The incomplete inhibition of IL-33 production by the anti-FccRII/III mAb should be due to the innate mechanisms as shown in the present study, in which intra-tracheal administration of OVA induced IL-33 production even in the non-sensitized mice. Therefore, the administered OVA was likely captured by the antigen-specific IgG antibody, and the antigen-antibody immune complex was then incorporated by the B-cells, alveolar macrophages and dendritic cells through FccRII/ III on their cell surface. This may be a substantial antigen-specific mechanism in the allergic IL-33 production.
In this study, it was also demonstrated that when the lung cells of the OVA+Al(OH) 3 -sensitized mice were incubated with DQ-OVA in vitro, the lung cells incorporated only small amounts of DQ-OVA, whereas when serum collected from the OVA+Al(OH) 3 -sensitized mice was added to the in vitro culture, the incorporation of DQ-OVA was markedly upregulated. Therefore, serum factors, such as antigen-specific IgG antibodies, may be required for the phagocytosis of OVA by lung cells. Additionally, the requirement of covalent interaction between complement C3b and the antigen-IgG immune complex has been suggested. shown. Mice were intraperitoneally (i.p.) treated with saline, Al(OH) 3 or OVA+Al(OH) 3 on days 0, 14 and 28. Then, the lungs were isolated followed by enzymatic digestion. Single cell suspension of the lung cells was incubated with DQ-OVA at 37°C for 30 min. Pooled serum collected from the saline-treated or OVA+Al(OH) 3 -sensitized mice was added to the cell suspension at a volume of 2Á5 ll/250 ll cell suspension/well. DQ-OVA-incorporated cells including alveolar macrophages were analysed by flow cytometer. Each point represents individual value. Mean AE SEM of four animals are also shown. **P < 0Á01; ***P < 0Á001. OVA, ovalbumin. The three types of phagocytic cells, B-cells, alveolar macrophages and dendritic cells, antigen-specifically incorporated OVA in the lung. Thus, we depleted B-cells and alveolar macrophages in the lungs. Although depletion of B-cells by the anti-CD20 mAb did not affect the antigen-induced IL-33 production, reduction of alveolar macrophages by clodronate liposomes partially but significantly suppressed IL-33 production. Taken together, it was suggested that alveolar macrophages incorporated the OVA-IgG antibody complex through FccRII/III on the cell surface, leading to IL-33 production. On the other hand, the number of dendritic cells was not reduced by clodronate liposomes. Uptake of liposomal-encapsulated clodronate has been demonstrated with monocytes and macrophages, and results in selective apoptosis. 30 Wang et al. 31 recently reported that clodronate liposomes selectively depleted immature dendritic cells but not mature dendritic cells. In our present study, dendritic cells were identified as CD45 + CD11c + I-A/I-E + cells, as previously reported. 11, 12, 22, 23, 25 As shown in Fig. 3d , the expression of I-A/I-E molecules on the dendritic cells was high, suggesting that the dendritic cells may have been a mature class of dendritic cells. The effect of clodronate liposomes on the dendritic cells suggests that the mature dendritic cells were not involved in the antigen-induced airway IL-33 production. However, the roles of the different dendritic cell subtypes in IL-33 production need to be clarified.
The present immunohistological analyses showed that the bronchial epithelial cells and smooth muscle cells, and alveolar macrophages produced IL-33 after the intra-tracheal antigen challenge. Our previous immunohistological study using the same kind of anti-IL-33 antibody showed that the bronchial epithelial cells were a major cellular source of IL-33 after the antigen challenge. 11 In the present study, the lung was perfused with PBS and then a large volume of 10% buffered formalin, before immersion in 10% buffered formalin although the perfusion procedure was not executed in our previous study. 11 The perfusion of the lung with 10% buffered formalin should have improved immunostainability of IL-33 especially in the bronchial smooth muscle cells and leucocytes. Tashiro et al. 32 also suggested that macrophages themselves are a cellular source of IL-33 in a murine model of allergic airway inflammation. Regarding the smooth muscle cells, to our knowledge, this is the first report to demonstrate that 2 From the results of the present study, alveolar macrophages incorporating OVA may have directly produced IL-33. Alternatively, the activated alveolar macrophages may directly or indirectly activate airway epithelial cells and smooth muscle cells to produce IL-33. In human bronchial epithelial cells in vitro, IL-33 is produced by stimulation with a major macrophage-derived cytokine, TNF-a. 33 It was reported that TNF-a increased the expression of IL-33 in the airway smooth muscle cells in vitro.
2 Oxidative stress may also serve as a key event for IL-33 release by the human airway epithelium. 34 The exact cellular sources of IL-33 associated with antigenspecific production need to be clarified.
In this study, it was suggested that IL-33 production from alveolar macrophages, airway epithelial cells and smooth muscle cells were augmented by the acquired immune system. It has become clear that IL-33 plays quite important roles in induction of type 2 inflammation via activation of IL-33 receptor, ST2 on ILC2 as well as Th2 cells, leading to production of type 2-associated cytokines, IL-5 and IL-13. 1, [5] [6] [7] In addition, IL-4 is also produced from ILC2 under a certain condition in the presence of Ca 2+ influx signal (Moro et al., unpublished data). Therefore, IL-33 production from airway cells should be one of indispensable mechanisms underlying pathogenesis of severe asthma.
In conclusion, intra-tracheally administered OVA was bound by the antigen-specific IgG antibody in the lung, and the immune complex was likely incorporated by alveolar macrophages through FccRII/III on the cell surface. This antigen-specific mechanism was involved in the antigen-induced IL-33 production in the lungs of sensitized mice. This mechanism may be useful for development of new pharmacotherapies for asthma.
